AUTHORS ' CONCLUSIONS Addition of ox and rolone to the GH therapy led to a modest increase in the final adult height of girls aged up to 18 years with TS .
BACKGROUND The final adult height of untreated girls aged up to 18 years with Turner syndrome ( TS ) is approximately 20 cm shorter compared with healthy females .
Treatment with growth hormone ( GH ) increases the adult height of people with TS .
The effects of adding the and rogen , ox and rolone , in addition to GH are unclear .
Therefore , we conducted this systematic review to investigate the benefits and harms of ox and rolone as an adjuvant therapy for people with TS treated with GH .
OBJECTIVES To assess the effects of ox and rolone on growth hormone-treated girls aged up to 18 years with Turner syndrome .
Growth hormone treatment of early growth failure in toddlers with Turner syndrome: a randomized, controlled, multicenter trial.
CONTEXT Typically , growth failure in Turner syndrome ( TS ) begins prenatally , and height sd score ( SDS ) declines progressively from birth . OBJECTIVE This study aim ed to determine whether GH treatment initiated before 4 yr of age in girls with TS could prevent subsequent growth failure . Secondary objectives were to identify factors associated with treatment response , to determine whether outcome could be predicted by a regression model using these factors , and to assess the safety of GH treatment in this young cohort . DESIGN This study was a prospect i ve , r and omized , controlled , open-label , multicenter clinical trial ( Toddler Turner Study , August 1999 to August 2003 ) . SETTING The study was conducted at 11 U.S. pediatric endocrine centers . SUBJECTS Eighty-eight girls with TS , aged 9 months to 4 yr , were enrolled . INTERVENTIONS Interventions comprised recombinant GH ( 50 mug/kg.d ; n = 45 ) or no treatment ( n = 43 ) for 2 yr . MAIN OUTCOME MEASURE The main outcome measure was baseline-to-2-yr change in height SDS . RESULTS Short stature was evident at baseline ( mean length/height SDS = -1.6 + /- 1.0 at mean age 24.0 + /- 12.1 months ) . Mean height SDS increased in the GH group from -1.4 + /- 1.0 to -0.3 + /- 1.1 ( 1.1 SDS gain ) , whereas it decreased in the control group from -1.8 + /- 1.1 to -2.2 + /- 1.2 ( 0.5 SDS decline ) , result ing in a 2-yr between-group difference of 1.6 + /- 0.6 SDS ( P < 0.0001 ) . The baseline variable that correlated most strongly with 2-yr height gain was the difference between mid-parental height SDS and subjects ' height SDS ( r = 0.32 ; P = 0.04 ) . Although attained height SDS at 2 yr could be predicted with good accuracy using baseline variables alone ( R(2 ) = 0.81 ; P < 0.0001 ) , prediction of 2-yr change in height SDS required inclusion of initial treatment response data ( 4-month or 1-yr height velocity ) in the model ( R(2 ) = 0.54 ; P < 0.0001 ) . No new or unexpected safety signals associated with GH treatment were detected . CONCLUSION Early GH treatment can correct growth failure and normalize height in infants and toddlers with TS
AUTHORS ' CONCLUSIONS Addition of ox and rolone to the GH therapy led to a modest increase in the final adult height of girls aged up to 18 years with TS .
BACKGROUND The final adult height of untreated girls aged up to 18 years with Turner syndrome ( TS ) is approximately 20 cm shorter compared with healthy females .
Treatment with growth hormone ( GH ) increases the adult height of people with TS .
The effects of adding the and rogen , ox and rolone , in addition to GH are unclear .
Therefore , we conducted this systematic review to investigate the benefits and harms of ox and rolone as an adjuvant therapy for people with TS treated with GH .
OBJECTIVES To assess the effects of ox and rolone on growth hormone-treated girls aged up to 18 years with Turner syndrome .